Ocufen Side Effects
Some of the reported side effects of Ocufen are burning, stinging, or irritation in the eye. Other common problems with this medication include eye redness, scarring of the eye, and dilation of the pupils. In most cases, reactions are minor and easy to treat. However, contact your healthcare provider if you have more serious problems, such as wheezing, blurred vision, or severe eye irritation.
Just like any medicine, Ocufen® (flurbiprofen ophthalmic) can cause side effects. However, not everyone who uses the medication will have problems. In fact, most people tolerate it quite well. If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider.
(This article covers many, but not all, of the possible side effects with Ocufen. Your healthcare provider can discuss a more complete list with you.)
For many medications, the prescribing information carefully explains the exact percentage of side effects that were seen in clinical trials. However, the prescribing information for some medicines, including Ocufen, includes only vague information on potential side effects, with no detail on how frequently the side effects occur. Therefore, it can be difficult to know exactly how common the side effects of such medications may be.
Some of the commonly reported Ocufen side effects include but are not limited to:
- Eye irritation
- Eye redness
- Scarring of the eye
- Bleeding in the front portion of the eye
- Constriction of the pupils
- Dilation of the pupils.
Some side effects of Ocufen are potentially serious and should be reported to your healthcare provider right away. These potential reactions include but are not limited to:
- Severe or prolonged burning, stinging, redness, or irritation in the eye
- Decreased or blurred vision
- Easy bruising or bleeding
- Unexplained eye pain
- Signs of an allergic reaction, such as:
- An unexplained rash
- Unexplained swelling of the mouth or throat
- Difficulty breathing or swallowing.